Product Description
Ocrelizumab, a humanized monoclonal antibody that selectively targets CD20+ B-cells, profoundly suppresses acute inflammatory disease activity, representing a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34354358/)
Mechanisms of Action: CD20 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting
Known Adverse Events: Respiratory Tract Infections
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Bosnia, Brazil, Bulgaria, Canada, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Hungary, India, Ireland, Israel, Italy, Kuwait, Latvia, Lebanon, Lithuania, Mexico, Morocco, Netherlands, New Zealand, Norway, Panama, Peru, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Tunisia, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States
Active Clinical Trial Count: 43
Highest Development Phases
Phase 3: Multiple Sclerosis|Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Relapsing-Remitting
Phase 2: Affective Disorders, Psychotic|Psychotic Disorders|Schizophrenia
Phase 1: Demyelinating Autoimmune Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| WA40404 | P3 |
Unknown Status |
Multiple Sclerosis |
2030-09-07 |
|
| OLERO | P3 |
Active, not recruiting |
Multiple Sclerosis |
2029-12-31 |
|
| OleroMAX | P3 |
Not yet recruiting |
Multiple Sclerosis |
2029-12-31 |
|
| WA39085 | P2 |
Unknown Status |
Multiple Sclerosis, Relapsing-Remitting |
2029-12-01 |